緑内障治療薬市場 - 成長予測、統計、事実 2031

  • Report Code : TIPRE00018828
  • Category : Pharmaceuticals
  • Status : Data Released
  • No. of Pages : 150
Buy Now

緑内障治療薬の市場規模は、2023 年の 62 億 4,000 万米ドルから 2031 年には 80 億 2,000 万米ドルに達すると予測されています。市場は 2023 年から 2031 年にかけて 3.2% の CAGR を記録すると予想されています。新しい薬物送達方法と併用療法の開発は、緑内障治療薬市場の主要なトレンドであり続けると思われます。

緑内障治療薬市場分析

緑内障は、神経組織が徐々に失われる眼疾患のグループであり、治療せずに放置すると最終的に視力喪失につながります。プロスタグランジン類似体は、眼からの排水を促進することで眼圧を下げるのに非常に効果的な薬剤の 1 つです。緑内障の罹患率の急増と新製品の発売の増加は、緑内障治療薬市場の成長に有利に働くと予想されます。

緑内障治療薬市場の概要

世界中で人口の高齢化が進み、緑内障の発症率が増加し、緑内障治療市場の成長に大きなチャンスが生まれています。高齢者層は緑内障にかかりやすいため、革新的な治療法や管理戦略の需要が高まっています。さらに、緑内障の早期発見と管理のための定期的な眼科検診の重要性から、患者の関与と高度な治療に対する需要が高まっています。ヘルスケア システムが高齢化社会のニーズに応えるようになると、緑内障の研究、開発、および治療へのアクセスへの投資が今後数年間で市場の成長を促進すると予想されます。

緑内障治療薬市場の推進要因と機会

緑内障疾患の増加が市場を後押し

緑内障研究財団によると、2022 年には約 8,000 万人が世界中で緑内障に罹患しています。2010 年には、世界中で約 840 万人が原発性開放隅角緑内障により視力を失っていました。緑内障研究財団によると、その数は 2040 年までに 2,200 万人に増加すると予測されています。これにより、今後、緑内障治療の需要が増加すると予想されます。緑内障の発症率が世界的に増加していることが、緑内障治療薬の世界市場を牽引する大きな要因となっています。

戦略的洞察

ウェアラブル技術の開発 - 緑内障治療薬のカスタマイズにおける機会

緑内障は失明の主な原因であり、早期発見と治療が不可欠です。ウェアラブル緑内障診断および治療薬が潜在的な解決策として浮上しています。従来の診断技術は信頼性の高い眼圧データを提供しますが、Sensimed Triggerfish などの新しいコンタクト レンズは、継続的な IOP 追跡を提供します。治療に関しては、薬剤溶出コンタクト レンズが潜在的な解決策として浮上しています。セラノスティック プラットフォームは、診断機能と治療機能を 1 つのデバイスに統合し、リアルタイムのモニタリングと個別化された投薬を提供します。

緑内障治療薬市場レポートのセグメンテーション分析

緑内障治療薬市場分析の導出に貢献した主要なセグメントは、薬物クラス、適応症、および流通チャネルです。

  • 薬物クラスに基づいて、緑内障治療薬市場は、ベータ遮断薬、アルファアドレナリン作動薬、プロスタグランジン類似体、炭酸脱水酵素阻害剤、併用薬、その他に分類されます。プロスタグランジン類似体セグメントは、2023年に最大の市場シェアを占めました。
  • 市場は、適応症によって開放隅角緑内障、閉塞隅角緑内障、その他に分類されています。開放隅角緑内障セグメントは、2023年に市場で最大のシェアを占めました。
  • 流通チャネルの面では、市場は病院薬局、小売薬局、オンライン薬局に分類されています。病院薬局セグメントは、2023年に市場を支配しました。

地域別の緑内障治療薬市場シェア分析

緑内障治療薬市場レポートの地理的範囲は、主に北米、アジア太平洋、ヨーロッパ、中東およびアフリカ、南米および中米の5つの地域に分かれています。

2022年には、約270万人のアメリカ人が開放隅角緑内障に罹患しました。緑内障は、米国における不可逆的な失明の主な原因でした。この地域での緑内障の発生率の上昇により、北米は2022年に最大のシェアを占めました。新しい併用療法や低侵襲性緑内障治療への傾向の高まりと、北米における主要な市場プレーヤーの存在は、この地域の緑内障治療市場の成長に貢献する要因です。

緑内障治療市場のニュースと最近の動向

緑内障治療市場は、重要な企業出版物、協会データ、データベースを含む一次調査と二次調査後の定性的および定量的データを収集することによって評価されます。以下は、緑内障治療薬の市場における動向の一覧です:

  • 米国食品医薬品局 (FDA) は、Glaukos Corporation の新薬申請 (NDA) を承認しました。iDose TR (トラボプロスト眼内インプラント) 75 mcg は、眼圧亢進 (OHT) または開放隅角緑内障 (OAG) 患者の眼圧 (IOP) を下げるためのプロスタグランジン類似体で、片眼に 1 回投与します。 (出典: Glaukos Corporation、企業ニュース、2023年)
  • アルコンは、Aerie Pharmaceuticals, Inc.の買収を発表しました。この取引を通じて、同社はRocklatan(ネタルスジルおよびラタノプロスト点眼液)0.02%/0.005%とRhopressa(ネタルスジル点眼液)0.02%、ドライアイ疾患の第3相候補であるAR-15512、およびいくつかの臨床および前臨床眼科医薬品候補のパイプラインを取得しました。RocklatanとRhopressaは、開放隅角緑内障または高眼圧症患者のIOP上昇を軽減する適応症を持つRhoキナーゼ阻害剤です。この買収により、緑内障、網膜、眼表面疾患にわたるアルコンのポートフォリオが拡大すると予想されます。 (出典: Alcon、プレスリリース、2022 年)

緑内障治療薬市場レポートの対象範囲と成果物

「緑内障治療薬市場の規模と予測 (2021-2031)」レポートでは、以下の分野を網羅した市場の詳細な分析を提供しています:

  • スコープ内の主要な市場セグメントすべてについて、世界、地域、国レベルでの市場規模と予測
  • 推進要因、制約、主要な機会などの市場動向
  • 主要な将来の傾向
  • 詳細な PEST および SWOT 分析
  • 主要な市場傾向、主要なプレーヤー、規制、および最近の市場動向を網羅した世界および地域の市場分析
  • 市場集中、ヒートマップ分析、主要なプレーヤー、および最近の動向を網羅した業界の状況と競争分析
  • 詳細な企業プロファイル
Report Coverage
Report Coverage

Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends

Segment Covered
Segment Covered

This text is related
to segments covered.

Regional Scope
Regional Scope

North America, Europe, Asia Pacific, Middle East & Africa, South & Central America

Country Scope
Country Scope

This text is related
to country scope.

Frequently Asked Questions


Which type segment dominates the glaucoma therapeutics market?

The glaucoma therapeutics market by drug class, is divided into beta blockers, alpha-adrenergic agonists, prostaglandin analogs, carbonic anhydrase inhibitors, combination drugs, and others. The prostaglandin analogs segment held a larger market share in 2023.

What was the estimated glaucoma therapeutics market size in 2023?

The glaucoma therapeutics informatics was valued at US$ 6.24 billion in 2023.

What factors drive the glaucoma therapeutics market?

Key factors driving the glaucoma therapeutics informatics growth are the surging prevalence of glaucoma and increasing product launches.

Who are the major players in the glaucoma therapeutics market?

The glaucoma therapeutics market majorly consists of the players, including Inoteck Pharmaceuticals; Merck & Co., Inc.; Novartis AG; Pfizer Inc.; Santen Pharmaceutical Co., Ltd.; Teva Pharmaceutical Industries Ltd; Takeda Pharmaceutical Company; AstraZeneca PLC; AERIE Pharmaceuticals, Inc.; and Cipla Inc.

What are glaucoma therapeutics?

Glaucoma is a group of eye disorders characterized by the gradual loss of nerve tissue that would eventually lead to vision loss if left untreated. Prostaglandin analogs are among the drugs that are highly effective in reducing eye pressure by promoting better drainage from the eye.

What are the growth estimates for the glaucoma therapeutics market till 2031?

The glaucoma therapeutics market is expected to be valued at US$ 8.02 billion in 2031.

The List of Companies - Glaucoma Therapeutics Market

  1. Fera Pharmaceuticals
  2. GlaxoSmithKline plc
  3. Bristol Myers Squibb
  4. Eli Lilly and Company
  5. Amgen
  6. MannKind Corporation
  7. Sangamo Therapeutics
  8. SciClone Pharmaceuticals, Inc.
  9. Critical Therapeutics, Inc.
  10. Takeda Pharmaceutical Company   

The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.

  1. Data Collection and Secondary Research:

As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.

Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.

  1. Primary Research:

The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.

For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.

A typical research interview fulfils the following functions:

  • Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
  • Validates and strengthens in-house secondary research findings
  • Develops the analysis team’s expertise and market understanding

Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:

  • Industry participants: VPs, business development managers, market intelligence managers and national sales managers
  • Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.

Below is the breakup of our primary respondents by company, designation, and region:

Research Methodology

Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.

  1. Data Analysis:

Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.

  • Macro-Economic Factor Analysis:

We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.

  • Country Level Data:

Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.

  • Company Profile:

The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.

  • Developing Base Number:

Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.

  1. Data Triangulation and Final Review:

The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.

We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.

We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.

Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Related Reports